Isabelle De Smedt focuses her practice on cross-border M&A and corporate transactions, complex litigation, the U.S. Foreign Corrupt Practices Act (FCPA) and related anti-corruption and fraud matters. As a licensed practitioner in Belgium and working primarily in Brussels, Isabelle is known for her keen ability to navigate the EU regulatory landscape. Her extensive regulatory compliance experience is crucial to guiding multinational clients through complex transactions. She also has substantial experience working with clients in the U.S., Europe, the Middle East, Asia and Latin America.
Isabelle is licensed to practice in Belgium and is a member of the Brussels Bar (List A). She is not admitted to practice in North Carolina or licensed to practice law in the United States.
Much of my practice involves cross-border transactions for health care and life sciences companies, including contract research organizations (CROs). I work with numerous international corporations, including many Belgian companies, on complex mergers, acquisitions, joint ventures and corporate restructuring and reorganizations. I also represent clients with respect to complex contract and corporate disputes.
A large piece of my international practice involves assisting clients with respect to the FCPA and other anti-corruption laws. This includes leading anti-corruption compliance investigations in connection with global mergers, acquisitions and joint ventures, as well as advising clients on issues relating to bribery and fraud matters. I work with clients to both establish and strengthen FCPA compliance programs and provide training sessions. I conduct internal investigations, risk assessments and due diligence interviews and guide clients through enforcement proceedings and government investigations when they arise.
I have a deep understanding of the distinct business models within the health care and life sciences industries, which allows me to tailor my approach to accommodate individual client’s needs and preferences.
Much stricter regulations for how companies deal with data will be enforced when the EU General Data Protection Regulation (GDPR) takes effect in 2018, causing a significant impact to companies operating in Europe. Companies that underestimate the impact of the new GDPR face the potential for significant fines if appropriate measures are not taken to comply.